BWXT Raises Full-Year Guidance After Strong Q2, Announces Medical Business Sale
The nuclear technology manufacturer posted second-quarter revenue of $901.6 million and lifted 2026 EBITDA guidance following strategic portfolio reshaping and PCG acquisition.
BWXT Beats Expectations, Refocuses on Core Nuclear Markets
BWX Technologies, Inc. (NYSE: BWXT) reported second-quarter 2026 results that exceeded internal expectations and raised its full-year financial guidance, while announcing strategic moves to concentrate on its nuclear defense and commercial power operations (8-K filing, 2026-08-03).
The Lynchburg, Virginia-based nuclear technology manufacturer posted second-quarter revenue of $901.6 million and net income of $89.1 million, translating to diluted GAAP earnings per share of $0.97 and non-GAAP EPS of $1.07 (8-K filing, 2026-08-03). Adjusted EBITDA for the quarter reached $155.5 million.
"We had strong second quarter 2026 results that were ahead of our expectations," said Rex D. Geveden, president and chief executive officer. "Once again we saw strong execution across our business, high growth in Commercial Operations, and good free cash flow generation" (8-K filing, 2026-08-03).
Portfolio Transformation and Expansion
BWXT announced the sale of its medical business, a move Geveden described as enabling "increased focus and resources" in the company's core nuclear national security and commercial nuclear power markets (8-K filing, 2026-08-03). The company emphasized that "demand for new nuclear solutions is remarkably deep and broad," complementing its existing revenue base.
Concurrently, BWXT closed the acquisition of Precision Components Group, LLC (PCG) on July 1, 2026, establishing what the company characterized as "a U.S. footprint for commercial nuclear component manufacturing" (8-K filing, 2026-08-03).
Segment Performance
Revenue growth materialized across both operating segments. Government Operations benefited from expansion in naval propulsion and special materials, though this was partially offset by lower advanced nuclear volumes. Commercial Operations saw gains across multiple areas, including commercial nuclear components, field services, fuel handling, medical operations, and contribution from its Kinectrics acquisition, with only slightly lower fuel revenue as a headwind (8-K filing, 2026-08-03).
Second-quarter GAAP operating income increased primarily due to Commercial Operations growth, though this was partially offset by lower Government Operations performance and higher corporate expenses (8-K filing, 2026-08-03).
Raised 2026 Guidance
"Reflecting our strong first half performance, contribution from the recently completed PCG acquisition, and confidence in our execution over the remainder of the year, we are raising our 2026 financial guidance," Geveden stated (8-K filing, 2026-08-03).
The company now anticipates adjusted EBITDA of $662 million to $672 million, non-GAAP EPS of $4.70 to $4.80, and free cash flow of $345 million to $360 million for full-year 2026 (8-K filing, 2026-08-03). The updated guidance incorporates the PCG acquisition contribution.
Shareholder Returns
BWXT paid a dividend of $24.7 million, or $0.27 per common share, to shareholders in the second quarter. On July 31, 2026, the board declared a quarterly cash dividend of $0.27 per share payable on September 4, 2026, to shareholders of record on August 18, 2026 (8-K filing, 2026-08-03).
According to MarginX data, recent insider activity included options exercises and tax withholdings by executive Cajade Gonzalo Raul.
This article was generated by MarginX from the 8-K filing on 2026-08-03. It is not investment advice.